Clinical Trials Directory

Trials / Completed

CompletedNCT03414632

Transthyretin Cardiac Amyloidosis in HFpEF

Prevalence of Transthyretin Cardiac Amyloidosis in Heart Failure With Preserved Ejection Fraction: A Community Study

Status
Completed
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
287 (actual)
Sponsor
Mayo Clinic · Academic / Other
Sex
All
Age
60 Years
Healthy volunteers
Not accepted

Summary

To estimate the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among Heart Failure with Preserved Ejection Fraction (HFpEF) patients with increased LV wall thickness in Southeast Minnesota using 99mTc-PYP single-photon positive emission computed tomography with computed tomography (SPECT/CT).

Detailed description

Residents of Southeast Minnesota over 60 years of age with an inpatient or outpatient diagnosis of heart failure (HF) will be consecutively identified in real-time using a natural language processing (NLP) search engine, their HF diagnosis validated, and those with a recent (≤ 12 months) echocardiogram documenting a preserved EF( ≥ 40%) and LV wall thickening will be consented to undergo venipuncture, urine collection and 99mTc-PYP SPECT/CT imaging to rule in/out the diagnosis of TTR-CA. Hence, the prevalence of TTR-CA will be defined. To place this prevalence in perspective of the global HFpEF cohort in the community, a rigorous screening log will be maintained to allow generation of a comprehensive CONSORT diagram. Importantly, baseline characteristics of patients who qualify for our study but decline to consent will still be collected provided that consent for use of their records for medical research had previously been granted.

Conditions

Interventions

TypeNameDescription
DRUG99mTc-PYPRadioisotope used in the SPECT/CT imaging

Timeline

Start date
2017-12-01
Primary completion
2020-03-31
Completion
2020-03-31
First posted
2018-01-30
Last updated
2021-03-19

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03414632. Inclusion in this directory is not an endorsement.